

Alan N. Engelman has received fees for serving as a speaker, and currently consults for ViiV Healthcare Co. Alan N. Engelman currently receives research funding from the US National Institutes of Health. Alan N. Engelman is an employee of the Dana-Farber Cancer Institute in Boston, Massachusetts. Alan N. Engelman is a co-inventor of US Patent 6,808,923, Episomally replicating lentiviral vectors, wherein lentiviral vectors for human gene therapy were engineered to express transgenes in the absence of integrase-mediated DNA recombination.